Thailand's H1N1 Flu Vaccine Maker Offers Trial Guidelines
This article was originally published in PharmAsia News
Thailand's Government Pharmaceutical Organization is issuing guidelines expected to limit clinical trials for its H1N1 flu vaccine to 430 volunteers between the age of 12 and 49 years old. The GPO plans to begin producing a nasal spray vaccine in August and to launch a four-month trial in September. The GPO drug represents Thailand's first attempt to make a vaccine from a live virus, developed under the aegis of the World Health Organization. (Click here for more
You may also be interested in...
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.